Pharmaron Selects Instem's Submit™ Software Suite for Complete SEND Management
Leading Chinese CRO at the Forefront of SEND Compliance in China
CONSHOHOCKEN, PA - August 16, 2016 - -Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that Chinese Contract Research Organization, Pharmaron, has purchased its full submit™ software solution suite to automate the creation and management of nonclinical data in accordance with CDISC’s Standard for Exchange of Nonclinical Data (SEND).
Founded in 2003, Pharmaron has over 10 years’ experience at the forefront of cutting edge research and development, and has been playing an important role in accelerating the drug discovery and development process for its partners by providing high quality of drug R&D services.
Pharmaron is proud to be recognized as one of China’s market leaders in the field of drug research and development services, and has invested in Instem’s submit™ solution suite to further strengthen its market leading position, particularly in the safety assessment area and to become one of the first CROs in the region to offer industry-leading SEND capabilities to its clients.
- Pharmaron has purchased the full submit™ software platform, a suite of integrated tools for the creation and management of SEND datasets and associated documents
- In addition, Pharmaron has selected Instem’s SENDView™ application to simplify the QC review and exploration of SEND datasets
- This investment follows the recent procurement of additional Provantis® user licenses and the Provantis Reproductive Toxicology module, demonstrating strong commitment to the Instem preclinical solution portfolio
Speaking on the recent purchases, Allison Perkins, Executive Director of Business Development at Pharmaron, said: “Over the past 10 years, Instem has helped us to remain at the forefront of the research & development sector by supplying robust, reliable, innovative software solutions and services. Our recent submit™ purchase, will strengthen our market-leading position, enabling us to provide consistent, accurate, high quality SEND datasets to our clients.”
Elaborating on the deal, Neil Donaldson, Vice President of Global Sales for Europe & Asia at Instem, commented: “Pharmaron were our first client in China, and we are deeply grateful for their continued support of and faith in our products. With the purchase of submit™, as well as the additional SENDView™ application, we are looking to help them retain their position as a market leader in their sector, as well as increase the productivity and efficiency of their service”.
Pharmaron is a private, premier R&D service provider for the life science industry. Founded in 2003, Pharmaron has invested in its people and facilities, and established a broad spectrum of drug R&D service capabilities, ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology, safety assessment, radiochemistry and radiolabeled metabolism to chemical & pharmaceutical development. With about 4,000 employees and operations in China, the U.S. and the U.K., Pharmaron has an excellent track record in the delivery of R&D solutions to its partners in North America, Europe, Japan and China. For more information, please visit:
Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.
Instem’s portfolio of software solutions and consulting services increases client productivity by enhancing product development processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.
Instem supports over 500 clients through offices in the United States, United Kingdom, Japan, China and India.
Gary Mitchell (US HQ)
Julie Jones (UK HQ)
Tel: +44 (0) 1785 825600